LEGN vs NVAX: fair value comparison
Legend Biotech Corporation and Novavax, Inc. · Updated 2026-10-19
LEGN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. NVAX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, LEGN currently ranks higher by quality score.
| LEGN | NVAX | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $18.48 | $11.26 |
| 12-month range | $16.65–$36.28 | $6.22–$12.82 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #85 of 301 Healthcare | #86 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: LEGN fair value analysis · NVAX fair value analysis